Penumbra Inc. (PEN)
Penumbra Inc. (PEN) Stock Price, Analysis & Data
| Bid | 323 |
| Market Cap | 12.88B |
| Revenue (ttm) | 1.5B |
| Net Income (ttm) | 160.59M |
| Beta | 0.70 |
| EPS (ttm) | 4.06 |
| PE Ratio (ttm) | 80.55 |
| Forward PE | 53.33 |
| P/B (ttm) | 8.41 |
| P/S (ttm) | 8.56 |
| Earnings Date | Nov 4, 2026 |
| Ask | 329 |
| Volume | 122,197 |
| Avg. Volume (20D) | 389,030 |
| Open | 327.28 |
| Previous Close | 326.75 |
| Day's Range | 326.75 - 328.11 |
| 52-Week Range | 221.26 - 362.41 |
| Analyst | Hold |
| Price Target | 374 (14.37%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About PEN
Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access prod...
Financial Performance
In 2025, Penumbra's revenue was 1.4B, an increase of 17.5% compared to the previous year's 1.19B. Earnings were 177.69M, an increase of 1,168.11%.
Financial StatementsAnalyst Forecast
According to 12 analyst ratings, the average rating for PEN stock is "Hold". The 12-month stock price forecast is 374, which is upside of 14.37% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
